Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Norhammar

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Diabetes Care|December 6, 2023
High Mannose Correlates With Surrogate Indexes of Insulin Resistance and Is Associated With an Increased Risk of Cardiovascular Events Independently of Glycemic Status and Traditional Risk FactorsElena Fortin, Beatrice Campi, Ele Ferrannini, et al.
Journal of Diabetes and Its Complications|September 8, 2023
Design and rationale of the myocardial infarction and new treatment with metformin study (MIMET) - Study protocol for a registry-based randomised clinical trialViveca Ritsinger, Emil Hagström, Kristina Hambraeus, et al.
European Journal of Heart Failure|June 16, 2021
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)Gianluigi Savarese, Johan Bodegard, Anna Norhammar, et al.
Diabetes Research and Clinical Practice|November 6, 2022
SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)Magnus Lundin, Giulia Ferrannini, Linda Mellbin, et al.
Scandinavian Cardiovascular Journal : SCJ|August 17, 2022
Long-term prognosis after a first myocardial infarction: eight years follow up of the case-control study PAROKRANKGiulia Ferrannini, Mariam Almosawi, Kåre Buhlin, et al.
Cardiovascular Diabetology|February 12, 2021
Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveysGiulia Ferrannini, Dirk De Bacquer, Pieter Vynckier, et al.
Diabetes Care|June 30, 2022
Measures of Insulin Resistance as a Screening Tool for Dysglycemia in Patients With Coronary Artery Disease: A Report From the EUROASPIRE V PopulationGiulia Ferrannini, Dirk De Bacquer, Iris Erlund, et al.
Cardiovascular Diabetology|March 5, 2025
Aortic valve calcification across stages of dysglycemia in middle-aged individuals from the general populationAnne Wang, Carl Johan Östgren, Anna Norhammar, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 studyCarolyn S P Lam, Avraham Karasik, Cheli Melzer-Cohen, et al.
Diabetes, Obesity & Metabolism|December 12, 2018
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational studyKåre I Birkeland, Johan Bodegard, Anna Norhammar, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Diabetes Care|December 6, 2023
High Mannose Correlates With Surrogate Indexes of Insulin Resistance and Is Associated With an Increased Risk of Cardiovascular Events Independently of Glycemic Status and Traditional Risk FactorsElena Fortin, Beatrice Campi, Ele Ferrannini, et al.
Journal of Diabetes and Its Complications|September 8, 2023
Design and rationale of the myocardial infarction and new treatment with metformin study (MIMET) - Study protocol for a registry-based randomised clinical trialViveca Ritsinger, Emil Hagström, Kristina Hambraeus, et al.
European Journal of Heart Failure|June 16, 2021
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)Gianluigi Savarese, Johan Bodegard, Anna Norhammar, et al.
Diabetes Research and Clinical Practice|November 6, 2022
SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)Magnus Lundin, Giulia Ferrannini, Linda Mellbin, et al.
Scandinavian Cardiovascular Journal : SCJ|August 17, 2022
Long-term prognosis after a first myocardial infarction: eight years follow up of the case-control study PAROKRANKGiulia Ferrannini, Mariam Almosawi, Kåre Buhlin, et al.
Cardiovascular Diabetology|February 12, 2021
Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveysGiulia Ferrannini, Dirk De Bacquer, Pieter Vynckier, et al.
Diabetes Care|June 30, 2022
Measures of Insulin Resistance as a Screening Tool for Dysglycemia in Patients With Coronary Artery Disease: A Report From the EUROASPIRE V PopulationGiulia Ferrannini, Dirk De Bacquer, Iris Erlund, et al.
Cardiovascular Diabetology|March 5, 2025
Aortic valve calcification across stages of dysglycemia in middle-aged individuals from the general populationAnne Wang, Carl Johan Östgren, Anna Norhammar, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 studyCarolyn S P Lam, Avraham Karasik, Cheli Melzer-Cohen, et al.
Diabetes, Obesity & Metabolism|December 12, 2018
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational studyKåre I Birkeland, Johan Bodegard, Anna Norhammar, et al.
Pageof 11